AGLE - Aeglea BioTherapeutics GAAP EPS of -$0.99 beats by $0.03 revenue of $2.33M beats by $0.1M
- Aeglea BioTherapeutics press release ( NASDAQ: AGLE ): FY GAAP EPS of -$0.99 beats by $0.03 .
- Revenue of $2.33M (-87.6% Y/Y) beats by $0.1M .
- As of December 31, 2022, Aeglea had available cash, cash equivalents, marketable securities and restricted cash of $57.3 million. The company expects its cash, cash equivalents and marketable securities will enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023.
For further details see:
Aeglea BioTherapeutics GAAP EPS of -$0.99 beats by $0.03, revenue of $2.33M beats by $0.1M